Sucampo Pharmaceuticals, Inc. 4
4 · Sucampo Pharmaceuticals, Inc. · Filed Mar 4, 2016
Insider Transaction Report
Form 4
Lichtlen Peter
Chief Medical Officer
Transactions
- Award
Employee Stock Option (right to buy)
2016-03-02+44,000→ 269,400 totalExercise: $13.80Exp: 2026-03-02→ Class A Common Stock (44,000 underlying)
Footnotes (1)
- [F1]The option vests in 4 equal annual installments beginning on March 2, 2017